Clinical trial
Comparison of Canagliflozin vs. Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Patients With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
NCT03492580 is registered in ClinicalTrials.gov with Janssen Research & Development, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Comparison of Canagliflozin vs. Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Patients With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
- Lead sponsor
- Janssen Research & Development, LLC
- Phase
- Observational
- Overall status
- Completed
- Start date
- February 22, 2018
- Completion date
- June 25, 2018
- Enrollment
- Not reported
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.